Emergent Biosolutions Gross Profit 2010-2022 | EBS

Emergent Biosolutions gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Emergent Biosolutions Annual Gross Profit
(Millions of US $)
2021 $1,035
2020 $1,031
2019 $673
2018 $460
2017 $373
2016 $363
2015 $382
2014 $303
2013 $251
2012 $236
2011 $231
2010 $239
2009 $189
Emergent Biosolutions Quarterly Gross Profit
(Millions of US $)
2022-09-30 $91
2022-06-30 $73
2022-03-31 $152
2021-12-31 $510
2021-09-30 $112
2021-06-30 $170
2021-03-31 $244
2020-12-31 $386
2020-09-30 $265
2020-06-30 $265
2020-03-31 $116
2019-12-31 $228
2019-09-30 $204
2019-06-30 $142
2019-03-31 $99
2018-12-31 $157
2018-09-30 $104
2018-06-30 $135
2018-03-31 $64
2017-12-31 $132
2017-09-30 $105
2017-06-30 $66
2017-03-31 $71
2016-12-31 $118
2016-09-30 $103
2016-06-30 $62
2016-03-31 $79
2015-12-31 $115
2015-09-30 $123
2015-06-30 $99
2015-03-31 $45
2014-12-31 $86
2014-09-30 $106
2014-06-30 $76
2014-03-31 $35
2013-12-31 $79
2013-09-30 $69
2013-06-30 $65
2013-03-31 $37
2012-12-31 $79
2012-09-30 $56
2012-06-30 $57
2012-03-31 $43
2011-12-31 $94
2011-09-30 $48
2011-06-30 $72
2011-03-31 $17
2010-12-31 $86
2010-09-30 $62
2010-06-30 $51
2010-03-31 $39
2009-12-31 $42
2009-09-30 $35
2009-06-30 $63
2009-03-31 $49
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.608B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $169.923B 10.37
GSK (GSK) United Kingdom $77.117B 9.67
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.058B 18.88
Ginkgo Bioworks Holdings (DNA) United States $3.317B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $2.305B 34.61
Biohaven (BHVN) United States $1.089B 0.00
Zymeworks (ZYME) Canada $0.443B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.262B 0.00
Enzo Biochem (ENZ) United States $0.087B 0.00
SQZ Biotechnologies (SQZ) United States $0.038B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00